IMRX Stock Overview
Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates.
Notes are coming soon
Immuneering Corporation Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$4.45|
|52 Week High||US$16.17|
|52 Week Low||US$3.74|
|1 Month Change||-8.25%|
|3 Month Change||-67.87%|
|1 Year Change||-55.50%|
|3 Year Change||n/a|
|5 Year Change||n/a|
|Change since IPO||-74.70%|
Recent News & Updates
|IMRX||US Biotechs||US Market|
Return vs Industry: IMRX underperformed the US Biotechs industry which returned 7.1% over the past year.
Return vs Market: IMRX underperformed the US Market which returned -9.2% over the past year.
|IMRX Average Weekly Movement||12.7%|
|Biotechs Industry Average Movement||12.2%|
|Market Average Movement||6.9%|
|10% most volatile stocks in US Market||17.3%|
|10% least volatile stocks in US Market||2.8%|
Stable Share Price: IMRX is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 13% a week.
Volatility Over Time: IMRX's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Immuneering Corporation, a biopharmaceutical company, focuses on the oncology and neuroscience product candidates. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 to treat solid tumors. The company also has five oncology programs in the discovery stage that are designed to target components of the MAPK or mTOR pathway; and two discovery stage neuroscience programs.
Immuneering Corporation Fundamentals Summary
|IMRX fundamental statistics|
Is IMRX overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|IMRX income statement (TTM)|
|Cost of Revenue||US$364.34k|
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
|Earnings per share (EPS)||-1.82|
|Net Profit Margin||-9,494.86%|
How did IMRX perform over the long term?See historical performance and comparison